Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: A time trade-off survey in five countries

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Evans, Marc ^a   Khunti, Kamlesh ^b   Mamdani, Muhammad ^c   Galbo Jørgensen, Claus B ^d   Gundgaard, Jens ^e   Bøgelund, Mette ^d   Harris, Stewart ^f  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d Holte Stationsvej 14   (Denmark)

^e NOVO NORDISK A S   (Denmark)

^f WESTERN UNIVERSITY   (Canada)

Author keywords

Disutility; Hypoglycaemia; Quality of life; Time trade off

Indexed keywords

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GERMANY; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; SWEDEN; TIME; UNITED KINGDOM; UNITED STATES; AGED; COMPARATIVE STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PSYCHOLOGICAL ASPECT;

ADULT; AGED; CANADA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; GREAT BRITAIN; HUMANS; HYPOGLYCEMIA; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SWEDEN; TIME FACTORS; UNITED STATES;

EID: 84878355445     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-90     Document Type: Article

References (48)

1. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP, DARTS/MEMO Collaboration Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005, 22:749-755. 10.1111/j.1464-5491.2005.01501.x, 15910627, DARTS/MEMO Collaboration.
2. European Medicines Agency Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500115945.pdf (Last accessed February 2013), European Medicines Agency.
3. Workgroup on Hypoglycemia. ADA Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005, 28:1245-1249. Workgroup on Hypoglycemia. ADA.
4. Yale J-F, Begg I, Gerstein H, Houlden R, Jones H, Maheux P, Pacaud D. 2001 Canadian diabetes association clinical practice guidelines for the prevention and management of hypoglycemia in diabetes. Can J Diabetes 2001, 28:22-35.
5. Hepburn DA. Symptoms of hypoglycemia. Hypoglycemia and diabetes: clinical and physiological aspects 1993, London: Edward Arnold, Frier BM.
6. Alvarez-Guisasola F, Yin DD, Nocea G, Qiu Y, Mavros P. Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. Health Qual Life Outcomes 2010, 8:86. 10.1186/1477-7525-8-86, 2936440, 20723229.
7. Brod M, Christiansen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycaemic events on work productivity and diabetes management. Value Health 2011, 14:665-671. 10.1016/j.jval.2011.02.001, 21839404.
8. Polonsky WH, Davis CL, Jacobson AM, Anderson BJ. Correlates of hypoglycemic fear in type I and type II diabetes mellitus. Health Psychol 1992, 11:199-202.
9. Green AJ, Fox KM, Grandy S, SHIELD Study Group Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract 2012, 96:313-318. 10.1016/j.diabres.2012.01.002, 22296853, SHIELD Study Group.
10. Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Diabet Med 2012, 29:293-302. 10.1111/j.1464-5491.2011.03416.x, 21838763.
11. Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab 2010, 36:S64-S74.
12. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002, 22:340-349.
13. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009, 12(Suppl 1):S5-S9.
14. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005, 21:1477-1483. 10.1185/030079905X61929, 16197667.
15. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycaemia. Eur J Health Econ 2005, 6:197-202. 10.1007/s10198-005-0276-3, 15761775.
16. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006, 22:1523-1534. 10.1185/030079906X115757, 16870077.
17. Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, Barber BL. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007, 16:1251-1265. 10.1007/s11136-007-9226-0, 17638121.
18. Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008, 6:73. 10.1186/1477-7525-6-73, 2567965, 18823555.
19. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoecon Outcomes Res 2002, 2:99-108. 10.1586/14737167.2.2.99, 19807322.
20. Torrance GW, Blaker D, Detsky A, Kennedy W, Schubert F, Menon D, Tugwell P, Konchak R, Hubbard E, Firestone T. Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. Pharmacoeconomics 1996, 9:535-539.
21. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal. 2008, http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (Last accessed January 2013) , National Institute for Health and Clinical Excellence.
22. Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ 1996, 5:141-154. 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N, 8733106.
23. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108. 10.1097/00005650-199711000-00002, 9366889.
24. Dolan P, Jones-Lee M. The time trade-off: a note on the effect of lifetime reallocation of consumption and discounting. J Health Econ 1997, 16:731-739. 10.1016/S0167-6296(96)00514-0, 10176781.
25. Dolan P. The measurement of individual utility and social welfare. J Health Econ 1998, 17:39-52. 10.1016/S0167-6296(97)00022-2, 10176314.
26. Robinson A, Dolan P, Williams A. Valuing health status using VAS and TTO: what lies behind the numbers?. Soc Sci Med 1997, 45:1289-1297. 10.1016/S0277-9536(97)00057-9, 9381241.
27. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989, 5:559-575. 10.1017/S0266462300008461, 2634630.
28. Torrance GW. Preferences for health outcomes and cost-utility analysis. Am J Manag Care 1997, 3(Suppl 1):S8-S20.
29. Dolan P. Aggregating health state valuations. J Health Serv Res Policy 1997, 2:160-165.
30. World Health Organization Life tables for WHO member states. http://apps.who.int/gho/data/node.main.687?lang=en (Last accessed October 2012) , World Health Organization.
31. Szende A, Brazier J, Schaefer C, Deuson R, Isitt JJ, Vyas P. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. Curr Med Res Opin 2010, 26:1893-1903. 10.1185/03007995.2010.494126, 20553121.
32. Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA. Willingness to pay for a QUALY based on community member and patient preferences for temporary health states associated with herpes zoster. PharmacoEconomics 2009, 27:1005-1016. 10.2165/11314000-000000000-00000, 19908925.
33. Chang WT, Collins ED, Kerrigan CL. An Internet-based utility assessment of breast hypertrophy. Plast Reconstr Surg 2001, 108:370-377. 10.1097/00006534-200108000-00014, 11496177.
34. Hurley J. An overview of the normative economics of the health sector. Chapter 2. Cost-effectiveness in Health and Medicine 1996, 62-67. New York: Oxford University Press, Inc., Gold MR, Siegel JE, Russell LB, Weinstein MC.
35. Dolan P. The measurement of health-related quality of life for use in resource allocation decisions in health care. Chapter 32. Handbook of Health Economics 2000, 1738-1740. Amsterdam: Elsevier (North Holland Publishing Co.), Culyer AJ, Newhouse JP.
36. Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, Daniels N, Weinstein MC. Identifying and Valuing Outcomes. Chapter 4. Cost-effectiveness in Health and Medicine 1996, 105-106. New York: Oxford University Press, Inc., Gold MR, Siegel JE, Russell LB, Weinstein MC.
37. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997, 6:327-340. 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W, 9285227.
38. Atkinson SE, Wilson PW. Comparing mean efficiency and productivity scores from small samples: a bootstrap methodology. J Prod Anal 1995, 6:137-152.
39. Efron B. Nonparametric estimates of standard error: the jackknife, the bootstrap and other methods. Biometrika 1981, 68:589-599.
40. Attema AE, Brouwer WB. The value of correcting values: influence and importance of correcting TTO scores for time preference. Value Health 2010, 13:879-884. 10.1111/j.1524-4733.2010.00773.x, 20659269.
41. Central Intelligence Agency (CIA) The World Factbook: United Kingdom [Internet] 2012, Washington, DC: CIA, https://www.cia.gov/library/publications/the-world-factbook/geos/uk.html (Last accessed October 2012) , Central Intelligence Agency (CIA).
42. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycaemia: an overview of fear of hypoglycaemia, quality-of-life, and impact on costs. J Med Econ 2011, 14:646-655. 10.3111/13696998.2011.610852, 21854191.
43. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989, 10:407-415. 10.1016/0197-2456(89)90005-6, 2691207.
44. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006, 4:70. 10.1186/1477-7525-4-70, 1586195, 17005038.
45. Luo N, Johnson JA, Coons SJ. Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care 2010, 48:365-371. 10.1097/MLR.0b013e3181c162a2, 20355266.
46. Pickard AS, Maureen P, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007, 5:70. 10.1186/1477-7525-5-70, 2248572, 18154669.
47. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003, 1:4. 10.1186/1477-7525-1-4, 155547, 12737635.
48. Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med 2001, 33:344-349. 10.3109/07853890109002088, 11491193.